Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock
Close on Oct 19, 2026Market cap $5.94MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $5.94M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.45
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.31M
- EPS, diluted
- -$1.40
- Book value per share
- $0.99
- Diluted shares
- 13M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $0.47
- Open
- $0.47
- Day's range
- $0.45 – $0.50
- Volume
- 34,085
- Average volume (20 days)
- 28,254
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | RVPH | S&P 500 | Difference | RVPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.2% | +0.6% | −6.9 pts | ||
| 3 months | -20.4% | +3.4% | −23.7 pts | ||
| Year to date | -91.9% | +13.3% | −105.2 pts | ||
| 1 year | -96.1% | +16.6% | −112.7 pts | ||
| 3 years | -99.4% | +86.4% | −185.8 pts | -81.8% | +23.1% |
| 5 years | -99.3% | +81.9% | −181.2 pts | -63.5% | +12.7% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Reviva Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Update
About Reviva Pharmaceuticals
Pharmaceutical Preparations
Reviva Pharmaceuticals Holdings, Inc. is a pharmaceutical company that focuses on the clinical development of therapeutic drug candidates. Its primary product candidate in development is brilaroxazine, a chemical compound under evaluation for the treatment of patients with schizophrenia. The company conducts clinical trials to assess the safety and efficacy of this candidate. Because Reviva is currently engaged in drug research and clinical trials, the text identifies no commercial operating segments, and its prospective users are individuals diagnosed with schizophrenia.
Company profile, executives and historyReviva Pharmaceuticals stock: common questions
What is Reviva Pharmaceuticals's stock price?
RVPH closed at $0.45 on Oct 19, 2026, down 4.36% on the day.
What is Reviva Pharmaceuticals's market cap?
Reviva Pharmaceuticals was worth $5.94M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is RVPH's P/E ratio?
Reviva Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.40), so it has no meaningful P/E ratio.
Does Reviva Pharmaceuticals pay a dividend?
No. Reviva Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Reviva Pharmaceuticals report earnings next?
Reviva Pharmaceuticals is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has RVPH stock performed over the past year?
Including dividends, RVPH returned -96.1% over the past year, against +16.6% for the S&P 500.
Who are Reviva Pharmaceuticals's competitors?
Companies most similar to Reviva Pharmaceuticals by business, industry and size include NERV, MPLT, KTTA, COGT, OVID.
See a number that looks wrong?